|
1
|
CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection.
|
Immunity
|
2010
|
2.16
|
|
2
|
Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV.
|
AIDS
|
2003
|
2.12
|
|
3
|
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters.
|
Thromb Haemost
|
2003
|
1.91
|
|
4
|
Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors.
|
EMBO J
|
2002
|
1.84
|
|
5
|
Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo.
|
Blood
|
2012
|
1.72
|
|
6
|
NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development.
|
EMBO J
|
2009
|
1.66
|
|
7
|
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.
|
Blood
|
2004
|
1.63
|
|
8
|
Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment.
|
Blood
|
2003
|
1.62
|
|
9
|
Dynamic antibody-binding properties in the pathogenesis of HIT.
|
Blood
|
2012
|
1.59
|
|
10
|
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.
|
Blood
|
2005
|
1.59
|
|
11
|
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin.
|
Blood
|
2004
|
1.50
|
|
12
|
The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy.
|
Blood
|
2010
|
1.40
|
|
13
|
Infusion of mature megakaryocytes into mice yields functional platelets.
|
J Clin Invest
|
2010
|
1.39
|
|
14
|
The clinical course and genetic defect in the PCFT gene in a 27-year-old woman with hereditary folate malabsorption.
|
J Pediatr
|
2008
|
1.36
|
|
15
|
Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.
|
Blood
|
2007
|
1.34
|
|
16
|
Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots.
|
Blood
|
2008
|
1.31
|
|
17
|
Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization.
|
Blood
|
2007
|
1.28
|
|
18
|
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis.
|
Thromb Res
|
2009
|
1.25
|
|
19
|
Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins.
|
Blood
|
2006
|
1.25
|
|
20
|
Determinants of PF4/heparin immunogenicity.
|
Blood
|
2007
|
1.25
|
|
21
|
Megakaryocyte biology and related disorders.
|
J Clin Invest
|
2005
|
1.23
|
|
22
|
Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets.
|
Blood
|
2003
|
1.18
|
|
23
|
Platelet factor 4 activity against P. falciparum and its translation to nonpeptidic mimics as antimalarials.
|
Cell Host Microbe
|
2012
|
1.16
|
|
24
|
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
|
Blood
|
2010
|
1.14
|
|
25
|
Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
|
Blood
|
2013
|
1.11
|
|
26
|
FOG1 requires NuRD to promote hematopoiesis and maintain lineage fidelity within the megakaryocytic-erythroid compartment.
|
Blood
|
2010
|
1.09
|
|
27
|
The relative role of PLCbeta and PI3Kgamma in platelet activation.
|
Blood
|
2005
|
1.09
|
|
28
|
Challenges and promises for the development of donor-independent platelet transfusions.
|
Blood
|
2013
|
1.09
|
|
29
|
Expression, purification and characterization of human glutamate dehydrogenase (GDH) allosteric regulatory mutations.
|
Biochem J
|
2002
|
1.08
|
|
30
|
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.
|
Blood
|
2010
|
1.08
|
|
31
|
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.
|
J Pharmacol Exp Ther
|
2009
|
1.05
|
|
32
|
Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.
|
Blood
|
2010
|
1.04
|
|
33
|
Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells.
|
J Biol Chem
|
2002
|
1.02
|
|
34
|
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.
|
Blood
|
2002
|
1.01
|
|
35
|
Quinine-dependent, platelet-reactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia.
|
Blood
|
2008
|
1.00
|
|
36
|
Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII.
|
Blood
|
2005
|
0.99
|
|
37
|
Induction of functional platelets from mouse and human fibroblasts by p45NF-E2/Maf.
|
Blood
|
2012
|
0.99
|
|
38
|
High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia.
|
Blood
|
2013
|
0.98
|
|
39
|
Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface.
|
Blood
|
2002
|
0.97
|
|
40
|
Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection.
|
J Clin Invest
|
2014
|
0.97
|
|
41
|
Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist.
|
Blood
|
2009
|
0.96
|
|
42
|
Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
|
J Clin Apher
|
2007
|
0.95
|
|
43
|
Identification of distal regulatory regions in the human alpha IIb gene locus necessary for consistent, high-level megakaryocyte expression.
|
Blood
|
2002
|
0.95
|
|
44
|
Interactions of platelet factor 4 with the vessel wall.
|
Semin Thromb Hemost
|
2004
|
0.94
|
|
45
|
PF4/heparin complexes are T cell-dependent antigens.
|
Blood
|
2005
|
0.93
|
|
46
|
Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes.
|
Blood
|
2009
|
0.93
|
|
47
|
Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller.
|
Blood
|
2008
|
0.92
|
|
48
|
Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine.
|
Exp Mol Med
|
2007
|
0.92
|
|
49
|
SLC35D3 delivery from megakaryocyte early endosomes is required for platelet dense granule biogenesis and is differentially defective in Hermansky-Pudlak syndrome models.
|
Blood
|
2012
|
0.91
|
|
50
|
The role of platelet factor 4 in radiation-induced thrombocytopenia.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.87
|
|
51
|
Inducible Gata1 suppression expands megakaryocyte-erythroid progenitors from embryonic stem cells.
|
J Clin Invest
|
2015
|
0.85
|
|
52
|
In vivo characterization of the integrin beta3 as a receptor for Hantaan virus cellular entry.
|
Exp Mol Med
|
2005
|
0.85
|
|
53
|
The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis.
|
J Clin Invest
|
2015
|
0.85
|
|
54
|
Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge.
|
Blood
|
2007
|
0.84
|
|
55
|
Loss of ATE1-mediated arginylation leads to impaired platelet myosin phosphorylation, clot retraction, and in vivo thrombosis formation.
|
Haematologica
|
2013
|
0.83
|
|
56
|
Medical countermeasures for platelet regeneration after radiation exposure. Report of a workshop and guided discussion sponsored by the National Institute of Allergy and Infectious Diseases, Bethesda, MD, March 22–23, 2010.
|
Radiat Res
|
2011
|
0.82
|
|
57
|
Development and licensure of medical countermeasures for platelet regeneration after radiation exposure.
|
Radiat Res
|
2011
|
0.81
|
|
58
|
Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis.
|
Blood
|
2012
|
0.81
|
|
59
|
Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction.
|
Blood
|
2011
|
0.81
|
|
60
|
Modulation of protein C activation by histones, platelet factor 4, and heparinoids: new insights into activated protein C formation.
|
Arterioscler Thromb Vasc Biol
|
2013
|
0.77
|
|
61
|
Mechanisms for mentored career development: the NIH research career awards and other national awards.
|
Hematology Am Soc Hematol Educ Program
|
2007
|
0.77
|
|
62
|
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.
|
Blood
|
2011
|
0.76
|
|
63
|
A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation.
|
J Clin Invest
|
2016
|
0.75
|
|
64
|
Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same?
|
J Genet Syndr Gene Ther
|
2011
|
0.75
|
|
65
|
Atherosclerosis is not a risk factor for anti-platelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery.
|
Thromb Haemost
|
2014
|
0.75
|
|
66
|
Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia.
|
J Clin Invest
|
2017
|
0.75
|
|
67
|
Current status of blood 'pharming': megakaryoctye transfusions as a source of platelets.
|
Curr Opin Hematol
|
2017
|
0.75
|
|
68
|
Role of monocytes and endothelial cells in heparin-induced thrombocytopenia.
|
Thromb Haemost
|
2016
|
0.75
|